Research summary
Type C retrovirus particles (HTLV strain CR) were detected in T-cell lymphoblastoid lines HUT 102 and CTCL-3 and in fresh peripheral blood lymphocytes from a mycosis fungoides patient; HUT 102 became a constitutive virus producer by passage 56 while CTCL-3 was constitutive from passage 2, with both mature and immature extracellular particles visualized [1]. An MTT-based semiautomated colorimetric drug-sensitivity assay was optimized for V79, CHO-AuxB1, CHRC5, NCI-H460 and NCI-H249 cell lines and benchmarked against clonogenic and dye-exclusion assays, with strong correlation in CHO-AuxB1 and the pleiotropic-drug-resistant CHRC5 mutant for 1-hour drug exposures [2]. The Lung Cancer Mutation Consortium ran multiplexed assays of 10 oncogenic-driver genes in lung adenocarcinomas across 14 U.S. sites from 2009-2012 to determine driver frequencies, guide targeted therapy selection and measure survival [3]. p53 was identified as a frequent target of genetic abnormalities in lung cancer, with homozygous deletions, abnormally sized mRNAs, and point/small mutations clustered in conserved regions of the open reading frame, plus very low or absent p53 mRNA expression [4]. A 76-gene epithelial-mesenchymal transition signature was developed and validated across four microarray platforms in NSCLC cell lines and BATTLE-study patients; the signature predicted resistance to EGFR and PI3K inhibitors and identified Axl as a therapeutic target for overcoming EGFR inhibitor resistance [5]. Massively parallel sequencing of small-cell lung cancer cell line NCI-H209 identified 22,910 somatic substitutions (134 in coding exons), with mutation signatures reflecting tobacco-carcinogen base-context preferences and evidence of transcription-coupled and expression-linked repair [6].
Recent publications
- Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomaDOI
- Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsDOI
- Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancerDOI
- Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model dataDOI
- p53: A Frequent Target for Genetic Abnormalities in Lung CancerDOI
- An Epithelial鈥揗esenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor ResistanceDOI
- Characterizing the cancer genome in lung adenocarcinomaDOI
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerDOI
- A small-cell lung cancer genome with complex signatures of tobacco exposureDOI
The lab page does not clearly state student acceptance status. Email the professor directly to confirm.
How to apply
Email John D. Minna 6-12 months before your application deadline. Read several recent papers and reference specific work in your message. Use our how to email a Japanese professor guide for the proven email structure.
For applications via MEXT scholarship: see our MEXT 2027 complete guide and university-specific University Recommendation track.
External profiles
- ORCID: https://orcid.org/0000-0002-7776-0767
- OpenAlex: openalex.org
Profile compiled from public sources (Researchmap, OpenAlex, Chiba University faculty directory). Last refreshed 2026-05. Report incorrect information.